Abstract
Using short peptide fragments of proteins to elicit antibodies able to recognize the protein from which the peptide sequence was derived, is one of the main goals in immunotherapy today. Indeed, peptide-immunotherapy appears as an obliged way to obtain antibodies of predetermined specificity and exempt from the complications associated with whole cells/entire protein vaccines. However, effective peptide-immunotherapy remains an exciting theoretical speculation largely unrealized to date. The major obstacle in designing effective peptide vaccines is our incapacity to scientifically define peptide immunogenicity. This mini-review schematically describes: 1) the available methods to identify epitopic peptides; 2) the sequence redundancy concept as a possible basis for peptide immunogenicity.
Keywords: Peptide-antibody interaction, antigenicity, immunogenicity, peptide features, redundant sequences
Current Drug Discovery Technologies
Title: Peptimmunology: Immunogenic Peptides and Sequence Redundancy
Volume: 2 Issue: 4
Author(s): Darja Kanduc
Affiliation:
Keywords: Peptide-antibody interaction, antigenicity, immunogenicity, peptide features, redundant sequences
Abstract: Using short peptide fragments of proteins to elicit antibodies able to recognize the protein from which the peptide sequence was derived, is one of the main goals in immunotherapy today. Indeed, peptide-immunotherapy appears as an obliged way to obtain antibodies of predetermined specificity and exempt from the complications associated with whole cells/entire protein vaccines. However, effective peptide-immunotherapy remains an exciting theoretical speculation largely unrealized to date. The major obstacle in designing effective peptide vaccines is our incapacity to scientifically define peptide immunogenicity. This mini-review schematically describes: 1) the available methods to identify epitopic peptides; 2) the sequence redundancy concept as a possible basis for peptide immunogenicity.
Export Options
About this article
Cite this article as:
Kanduc Darja, Peptimmunology: Immunogenic Peptides and Sequence Redundancy, Current Drug Discovery Technologies 2005; 2 (4) . https://dx.doi.org/10.2174/157016305775202946
DOI https://dx.doi.org/10.2174/157016305775202946 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Molecular Delivery of Plasmids for Genetic Vaccination
Current Pharmaceutical Biotechnology Nanoemulsion Strategy for Ursolic and Oleanic Acids Isolates from Plumeria Obtusa Improves Antioxidant and Cytotoxic Activity in Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells
Current Pharmaceutical Biotechnology Soluble Factors of Amnion-Derived Cells in Treatment of Inflammatory and Fibrotic Pathologies
Current Stem Cell Research & Therapy MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Targeting the Progression of Parkinsons Disease
Current Neuropharmacology Heterogeneity Amongst 5-HT3 Receptor Subunits: Is this Significant?
Current Molecular Medicine Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Post-Exercise Ketosis, Salivary Uric Acid and Interleukin-6 after a Simulated Wheelchair Basketball Match
Endocrine, Metabolic & Immune Disorders - Drug Targets Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry MUC1 Story: Great Expectations, Disappointments and the Renaissance
Current Medicinal Chemistry Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Advances in Vaccine Adjuvants For Infectious Diseases
Current HIV Research Study About the Knowledge and Attitudes of the Portuguese Population About Food Fibres
Current Nutrition & Food Science